8-K: Nurix Therapeutics Announces Positive Clinical Trial Results for NX-5948 in Relapsed/Refractory CLL

Nurix Therapeutics reported a 69.2% objective response rate in a Phase 1 clinical trial of NX-5948 for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), including those with BTK inhibitor resistance.

Summary

• Nurix Therapeutics announced updated clinical data from its Phase 1 trial of NX-5948, an oral BTK degrader, at the European Hematology Association Congress (EHA2024).
• The study included 79 patients in the Phase 1a dose escalation, with efficacy data for 31 patients with relapsed or refractory CLL.
• NX-5948 was administered orally at doses ranging from 50 mg to 600 mg daily and was generally well-tolerated.
• The most common adverse events were purpura/contusion, thrombocytopenia, and neutropenia.
• Among 26 efficacy-evaluable CLL patients, the objective response rate (ORR) was 69.2% across all doses.
• Responses were observed as early as the first scan (8 weeks) and deepened with longer treatment duration.
• All responses were ongoing as of the April 17, 2024 data cutoff.
• The CLL patient cohort was heavily pretreated, with a median of four prior lines of therapy, including prior BTK and BCL2 inhibitors.
• A significant number of patients had mutations associated with BTK inhibitor resistance, including BTK (43.3%) and PLC2G (20.0%) mutations.
• Responses were observed across all patient populations, regardless of prior treatment, baseline mutations, or CNS involvement.
• Nurix plans to advance NX-5948 into pivotal trials in 2025.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with a high objective response rate, good tolerability, and plans for rapid advancement to pivotal trials. The sentiment is very optimistic and suggests a strong potential for the drug.

Positives

• The 69.2% objective response rate is very promising, especially in a heavily pretreated CLL population.
• The rapid onset of responses, with many seen at the first scan, is a positive indicator.
• The deepening of responses over time suggests a durable treatment effect.
• The drug was well-tolerated across all doses, indicating a favorable safety profile.
• Responses were observed in patients with BTK inhibitor resistance mutations, addressing a significant unmet need.
• The drug showed activity in patients with CNS involvement, which is a difficult-to-treat condition.
• The company plans to move rapidly to pivotal trials in 2025, indicating confidence in the drug's potential.

Negatives

• The most common treatment emergent adverse events were purpura/contusion, thrombocytopenia and neutropenia, which may require monitoring and management.
• Some patients experienced grade 3 adverse events, including thrombocytopenia and neutropenia.
• There were some discontinuations due to radiological and clinical progression.

Risks

• The drug is still in clinical trials, and there is no guarantee of regulatory approval.
• The long-term safety and efficacy of NX-5948 are not yet fully established.
• The company may face challenges in funding the development and commercialization of the drug.
• There are risks associated with the drug development process, including unexpected adverse events.
• The company is subject to risks and uncertainties related to the timing and results of clinical trials.

Future Outlook

Nurix intends to expand the Phase 1b portion of the trial across a range of CLL subpopulations and initiate pivotal trials for NX-5948 in 2025. They also plan to present additional data from the study for both CLL and NHL as it matures.

Management Comments

• Dr. Kim Linton stated that the results are very impressive for this early stage of development and that NX-5948 has the potential to be an exciting breakthrough for patients with relapsed CLL.
• Paula G. OConnor, M.D., mentioned that they will expand the Phase 1b portion of the trial to prepare for initiation of pivotal, registration-directed clinical evaluation in 2025.
• Arthur T. Sands, M.D., Ph.D., stated that NX-5948 is emerging as a best-in-class medicine and that they intend to move rapidly forward with the goal of initiating pivotal trial(s) in 2025.

Industry Context

This announcement is significant as it addresses the growing challenge of resistance to existing BTK inhibitors in CLL treatment. The positive results for NX-5948, a BTK degrader, suggest a potential new treatment option for patients who have failed other therapies. This is in line with the industry's focus on developing novel therapies to overcome drug resistance in cancer.

Comparison to Industry Standards

• The 69.2% ORR in heavily pretreated CLL patients is competitive with other novel therapies in development for relapsed/refractory CLL.
• Existing BTK inhibitors like ibrutinib, acalabrutinib, and zanubrutinib have shown efficacy in CLL, but resistance is a major issue. NX-5948's activity in patients with BTK inhibitor resistance mutations is a key differentiator.
• BCL2 inhibitors like venetoclax are also used in CLL, and NX-5948's activity in patients who have progressed on BCL2 inhibitors is notable.
• The ability of NX-5948 to penetrate the central nervous system and show activity in patients with CNS involvement is a significant advantage over many existing therapies.
• The rapid and deepening responses observed with NX-5948 are comparable to or better than some other experimental therapies in this space.

Stakeholder Impact

• Shareholders: The positive clinical trial results are likely to be viewed favorably by investors, potentially increasing the company's stock price.
• Patients: The results offer hope for a new treatment option for patients with relapsed or refractory CLL, including those with resistance to existing therapies.
• Employees: The positive results may boost employee morale and confidence in the company's research and development efforts.
• Healthcare providers: The data provides valuable information for healthcare providers treating patients with CLL, potentially leading to new treatment strategies.

Next Steps

• Expand the Phase 1b portion of the trial across a range of CLL subpopulations.
• Initiate pivotal trials for NX-5948 in 2025.
• Present additional data from the study for both CLL and NHL in the second half of 2024.
• Expand Phase 1b in selected NHL subtypes with initial focus on monotherapy in indolent indications.

Key Dates

Keywords

NX-5948, BTK degrader, Chronic Lymphocytic Leukemia, CLL, B-cell malignancies, Objective Response Rate, ORR, Clinical Trial, EHA2024, Protein Degradation, Bruton's Tyrosine Kinase, Targeted Therapy, Cancer Treatment, Hematology, Oncology